NASDAQ$TEM
Tempus AI Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Tempus AI reported Q1 2025 total net revenue of $255.7M with a net loss of $68.0M and diluted EPS of $(0.40).
Total net revenue grew to $255.7 million, up 75% year over year, driven by genomics test volume and data/services growth including the Ambry acquisition. Net loss attributable to common shareholders was $68.0 million, or $0.40 per diluted share.
- Q1 total net revenue $255.7M (+75% YoY).
- Net loss $68.0M; diluted EPS $(0.40).
- Genomics and Insights product lines expanding.
- Ambry acquisition added hereditary testing volume.
Headline financials
Revenue & EPS history
Tempus AI Inc · Revenue · Quarterly
$256M
Revenue by segment
Tempus AI Inc · $146M total across 2 segments · Q1 2024
- Diagnostics$103M—70.3%
- Data and Applications$43.3M—29.7%
Forward guidance
Tempus highlights genomics volume, AI data products, and Ambry integration; pre-profit scale company.
Tailwinds
- Revenue +75% YoY on testing and data.
- Ambry adds hereditary testing capacity.
- Insights and pharma partnerships.
Headwinds
- Integration and cost to serve.
- Reimbursement and payer dynamics.
- Path to profitability still ahead.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q1 2025
-0.5%
Avg return
Earnings day
+10.9%
Avg return
5 days after
+12.9%
Avg return
30 days after
50%
5 / 10 earnings
Positive
+12.6%
Q1 2025
Best reaction
-15.0%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.1% | -10.7% | -7.2% | |
| Q4 2025 | +3.6% | -8.0% | -26.5% | |
| Q3 2025 | -2.7% | -15.0% | -9.3% | |
| Q2 2025 | +3.4% | +18.5% | +35.5% | |
| Q1 2025 | +12.6% | +20.1% | +18.9% | |
| Q4 2024 | -15.0% | -19.2% | -25.3% | |
| Q3 2024 | -3.4% | +60.2% | +25.9% | |
| Q3 2023 | -3.4% | +60.2% | +25.9% | |
| Q2 2024 | +1.6% | +1.4% | +45.6% | |
| Q2 2023 | +1.6% | +1.4% | +45.6% | |
| Q1 2024 | — | — | — | |
| Q1 2023 | — | — | — | |
| Q4 2022 | — | — | — | |
| Q3 2021 | — | — | — | |
| Q3 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro